Literature DB >> 12602518

Positron emission tomography in the study of hepatic encephalopathy.

Alan H Lockwood1.   

Abstract

Positron emission tomography (PET) is a powerful and versatile tool for the investigation of hepatic encephalopathy (HE). This nuclear medicine imaging technique produces quantitative images of the distribution of a radiopharmaceutical at one or more times after its administration. Thus, PET images can be used as data in mathematical models of physiologically important processes, including cerebral blood flow, an index of neural activity, or glucose and ammonia metabolism. Using PET, we have demonstrated abnormalities in all of these processes in patients, even though many had only minimal HE. In HE patients we have found increases in the cerebral ammonia metabolic rate, because of hyperammonemia and an increase in the permeability of the blood-brain barrier to ammonia and abnormal patterns of blood flow and glucose metabolism. In a recent collaborative study, alterations in the resting glucose metabolic rate were found to have significant correlations with a variety of neuropsychological tests used to detect mild HE including Trailmaking A and B, symbol-digit, and other tests. Activation techniques have not yet been applied to map sites affected by HE, but recent data using the paced serial auditory addition test and an auditory continuous performance task have proven to be sensitive indicators in minimally impaired patients. The full potential of PET to evaluate neurotransmitter function is as yet unrealized.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12602518     DOI: 10.1023/a:1021978422783

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  14 in total

1.  Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics.

Authors:  Alan H Lockwood; Karin Weissenborn; Martin Bokemeyer; U Tietge; Wolfgang Burchert
Journal:  Metab Brain Dis       Date:  2002-03       Impact factor: 3.584

2.  Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy.

Authors:  G A Macdonald; K A Frey; B W Agranoff; S Minoshima; R A Koeppe; D E Kuhl; B L Shulkin; M R Lucey
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

3.  Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy.

Authors:  A H Lockwood; E W Yap; H M Rhoades; W H Wong
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

Review 4.  Attentional networks.

Authors:  M I Posner; S Dehaene
Journal:  Trends Neurosci       Date:  1994-02       Impact factor: 13.837

5.  Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy.

Authors:  R E Tarter; A M Hegedus; D H Van Thiel; R R Schade; J S Gavaler; T E Starzl
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

6.  Affinities and densities of high-affinity [3H]muscimol (GABA-A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy.

Authors:  R F Butterworth; J Lavoie; J F Giguère; G Pomier-Layrargues
Journal:  Hepatology       Date:  1988 Sep-Oct       Impact factor: 17.425

7.  Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy.

Authors:  A H Lockwood; B W Murphy; K Z Donnelly; T C Mahl; S Perini
Journal:  Hepatology       Date:  1993-11       Impact factor: 17.425

8.  Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport.

Authors:  G M Knudsen; H E Poulsen; O B Paulson
Journal:  J Hepatol       Date:  1988-04       Impact factor: 25.083

Review 9.  Localization of cognitive operations in the human brain.

Authors:  M I Posner; S E Petersen; P T Fox; M E Raichle
Journal:  Science       Date:  1988-06-17       Impact factor: 47.728

10.  Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis.

Authors:  R Jalan; N Turjanski; S D Taylor-Robinson; M J Koepp; M P Richardson; J A Wilson; J D Bell; D J Brooks
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

View more
  6 in total

Review 1.  Energy metabolism in brain cells: effects of elevated ammonia concentrations.

Authors:  Leif Hertz; Geeta Kala
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 2.  Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy.

Authors:  V-P Bob Grover; M-Alex Dresner; Daniel-M Forton; Serena Counsell; David-J Larkman; Nayna Patel; Howard-C Thomas; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

3.  Magnetic resonance T2-relaxometry and 2D L-correlated spectroscopy in patients with minimal hepatic encephalopathy.

Authors:  Aparna Singhal; Rajakumar Nagarajan; Rajesh Kumar; Amir Huda; Rakesh K Gupta; M Albert Thomas
Journal:  J Magn Reson Imaging       Date:  2009-11       Impact factor: 4.813

Review 4.  [Hepatic encephalopathy].

Authors:  P D Schellinger; M K Hartmann; Ch Klingmann; H M Meinck
Journal:  Nervenarzt       Date:  2003-12       Impact factor: 1.214

5.  Multi-Sensory Integration Impairment in Patients with Minimal Hepatic Encephalopathy.

Authors:  Kyoungwon Seo; Dae Won Jun; Jae-Kwan Kim; Hokyoung Ryu
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

6.  Machine Learning Classification of Cirrhotic Patients with and without Minimal Hepatic Encephalopathy Based on Regional Homogeneity of Intrinsic Brain Activity.

Authors:  Qiu-Feng Chen; Hua-Jun Chen; Jun Liu; Tao Sun; Qun-Tai Shen
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.